Chicoric acid supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesis via inhibition of NF-κB

FASEB J. 2017 Apr;31(4):1494-1507. doi: 10.1096/fj.201601071R. Epub 2016 Dec 21.

Abstract

Chicoric acid (CA), a natural phenolic acid extracted from chicory and the echinacea (purple coneflower) plant (Echinacea purpurea), has been regarded as a nutraceutical that has powerful antioxidant and antiobesity activities. We investigated the inhibitory effects of CA on systemic inflammation-induced neuroinflammation, amyloidogenesis, and cognitive impairment. C57BL/6J mice were treated with 0.05% CA in the drinking water for 45 d. The mice were then treated by intraperitoneal injection of lipopolysaccharide (LPS). It was found that CA prevented LPS-induced memory impairment and neuronal loss through behavioral tests and histological examination. Furthermore, amyloidogenesis in the CNS was detected. The results showed that CA prevented LPS-induced increases in amyloid β (1-42 specific) (Aβ1-42) accumulation, levels of amyloid precursor protein, and neuronal β-secretase 1 (BACE1), as well as the equilibrium cholinergic system in mouse brain. Moreover, CA down-regulated LPS-induced glial overactivation by inhibiting the MAPK and NF-κB pathway. Consequently, CA reduced the levels of NF-κB transcriptionally regulated inflammatory mediators and cytokines such as iNOS, cyclooxygenase-2 (COX-2), IL-1β, and TNF-α in both mouse brain and BV2 microglial cells. These results demonstrated that CA alleviated memory impairment and amyloidogenesis triggered by LPS through suppressing NF-κB transcriptional pathway, suggesting that CA might be a plausible therapeutic intervention for neuroinflammation-related diseases such as Alzheimer disease.-Liu, Q., Chen, Y., Shen, C., Xiao, Y., Wang, Y., Liu, Z., Liu, X. Chicoric acid supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesis via inhibition of NF-κB.

Keywords: NF-κB transcriptional pathway; amyloid peptides accumulation; lipopolysaccharide; natural phenolic acid; neuroinflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / metabolism
  • Amyloid beta-Peptides / metabolism*
  • Amyloidosis / drug therapy*
  • Amyloidosis / etiology
  • Amyloidosis / prevention & control
  • Animals
  • Aspartic Acid Endopeptidases / metabolism
  • Caffeic Acids / pharmacology*
  • Caffeic Acids / therapeutic use
  • Cell Line
  • Cyclooxygenase 2 / metabolism
  • Interleukin-1beta / metabolism
  • Lipopolysaccharides / toxicity
  • Memory Disorders / drug therapy*
  • Memory Disorders / etiology
  • Memory Disorders / prevention & control
  • Mice
  • Mice, Inbred C57BL
  • Microglia / drug effects
  • Microglia / metabolism
  • NF-kappa B / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Nitric Oxide Synthase Type II / metabolism
  • Peptide Fragments / metabolism*
  • Succinates / pharmacology*
  • Succinates / therapeutic use
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Amyloid beta-Peptides
  • Caffeic Acids
  • Interleukin-1beta
  • Lipopolysaccharides
  • NF-kappa B
  • Neuroprotective Agents
  • Peptide Fragments
  • Succinates
  • Tumor Necrosis Factor-alpha
  • amyloid beta-protein (1-42)
  • Nitric Oxide Synthase Type II
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • Bace1 protein, mouse
  • chicoric acid